Literature DB >> 11008018

Differences in megakaryocyte expansion potential between CD34(+) stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children.

S van den Oudenrijn1, A E von dem Borne, M de Haas.   

Abstract

OBJECTIVE: Reinfusion of ex vivo expanded autologous megakaryocytes together with stem cell transplantation may be useful to prevent or reduce the period of chemotherapy-induced thrombocytopenia. We compared the megakaryocyte expansion potential of CD34(+) stem cells derived from different sources: cord blood (CB), peripheral blood (PB), bone marrow from adults (ABM), and bone marrow from children (ChBM). Three different growth factor combinations were tested to identify the best combination for each of the sources.
MATERIALS AND METHODS: CD34(+) cells were isolated from CB, PB, ABM, or ChBM and cultured in an in vitro liquid culture system in the presence of thrombopoietin (Tpo), Tpo + interleukin (IL-1), or Tpo + IL-3. After 8 days, proliferation was determined and the cultured cells were identified with lineage-specific surface markers by flow cytometry.
RESULTS: Cultures with ChBM-derived CD34(+) cells showed the lowest level of expansion of megakaryocytes and gave rise to more profound formation of myeloid and monocytic cells. In cultures with BM- or PB-derived cells, presence of IL-3 reduced the number of immature megakaryocytes (CD34(+)CD41(+) cells). However, in CB cultures, the number of CD34(+)CD41(+) cells was highest in cultures with Tpo + IL-3. Overall, cultures with CB CD34(+) cells yielded the highest number of megakaryocytes, but these cells showed reduced ploidization and lower level of CD41 expression, suggesting less maturation.
CONCLUSIONS: Each of the different CD34(+) cell sources responded differently to cytokine stimulation. For PB and ABM, the cytokine combination Tpo + IL-1 is most suitable to obtain high numbers of both immature and mature megakaryocytes for transfusion purposes. For CB, Tpo + IL-3 is better.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008018     DOI: 10.1016/s0301-472x(00)00517-8

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  Mesenchymal stromal cells lower platelet activation and assist in platelet formation in vitro.

Authors:  Avital Mendelson; Ana Nicolle Strat; Weili Bao; Peter Rosston; Georgia Fallon; Sophie Ohrn; Hui Zhong; Cheryl Lobo; Xiuli An; Karina Yazdanbakhsh
Journal:  JCI Insight       Date:  2019-08-22

2.  Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.

Authors:  Swapna Panuganti; Eleftherios T Papoutsakis; William M Miller
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

Review 3.  Recent developments in ex vivo platelet production.

Authors:  Retno Wahyu Nurhayati; Yoshihiro Ojima; Masahito Taya
Journal:  Cytotechnology       Date:  2016-03-22       Impact factor: 2.058

4.  Stem cell factor-displaying simian immunodeficiency viral vectors together with a low conditioning regimen allow for long-term engraftment of gene-marked autologous hematopoietic stem cells in macaques.

Authors:  Els Verhoeyen; Francis Relouzat; Marie Cambot; Caroline Costa; Didier Nègre; Faézeh Legrand; Christophe Joubert; Roger Le Grand; François-Loïc Cosset; Philippe Leboulch; Anne Dubart-Kupperschmitt; Stephane Prost
Journal:  Hum Gene Ther       Date:  2012-07-11       Impact factor: 5.695

Review 5.  In vitro megakaryocyte production and platelet biogenesis: state of the art.

Authors:  Jo-Anna Reems; Nicolas Pineault; Sijie Sun
Journal:  Transfus Med Rev       Date:  2010-01

6.  Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations.

Authors:  Joshua Kellner; Sufang Li; Patrick A Zweidler-McKay; Elizabeth J Shpall; Ian McNiece
Journal:  Cytotherapy       Date:  2014-12-19       Impact factor: 5.414

7.  Three-stage ex vivo expansion of high-ploidy megakaryocytic cells: toward large-scale platelet production.

Authors:  Swapna Panuganti; Alaina C Schlinker; Paul F Lindholm; Eleftherios T Papoutsakis; William M Miller
Journal:  Tissue Eng Part A       Date:  2013-01-14       Impact factor: 3.845

8.  Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins.

Authors:  Iain C Macaulay; Marloes R Tijssen; Daphne C Thijssen-Timmer; Arief Gusnanto; Michael Steward; Philippa Burns; Cordelia F Langford; Peter D Ellis; Frank Dudbridge; Jaap-Jan Zwaginga; Nicholas A Watkins; C Ellen van der Schoot; Willem H Ouwehand
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

9.  The High Yield Expansion and Megakaryocytic Differentiation of Human Umbilical Cord Blood CD133(+) Cells.

Authors:  Mahin Nikougoftar Zarif; Masoud Soleimani; Hassan Abolghasemi; Naser Amirizade; Saeid Abroun; Saeid Kaviani
Journal:  Cell J       Date:  2011-09-23       Impact factor: 2.479

Review 10.  Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP.

Authors:  Moyra Lawrence; Amanda Evans; Thomas Moreau; Marta Bagnati; Matthew Smart; Enas Hassan; Jahid Hasan; Monica Pianella; Julie Kerby; Cedric Ghevaert
Journal:  NPJ Regen Med       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.